A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy
Related Experiment Video
Updated: Aug 27, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Yu Wang1, Yan Tang1, Xiao-Mei Zhao1
1Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Jiangsu Suzhou 215123, China.
Abstract:
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system adapted from bacteria is a programmable nuclease-based genome editing tool. The long-lasting effect of gene silencing or correction is beneficial in cancer treatment. Considering the need to broaden the practical application of this technology, highly efficient non-viral vectors are urgently required. We prepared a multifunctional non-viral vector that could actively target tumor cells and deliver CRISPR/Cas9 plasmids into nuclei of cancer cells. Protamine sulfate (PS) which contains nuclear localization sequence was utilized to condense plasmid DNA and facilitate nuclei-targeted delivery. Liposome-coated protein/DNA complex avoided the degradation of nuclease in blood circulation. The obtained PS@Lip/pCas9 was further modified with distearoyl phosphoethanolamine-polyethylene glycol-hyaluronic acid (HA) to endow the vector ability to actively target tumor cell. Results suggested that PS@HA-Lip could deliver CRISPR/Cas9 plasmids into nuclei of tumor cells and induce genome editing effect. With the disruption of MTH1 (mutT homolog1) gene, the growth of non-small cell lung cancer was inhibited. Moreover, cell apoptosis in tumor tissue was promoted, and liver metastasis of non-small cell lung cancer (NSCLC) was reduced. Our study has provided a therapeutic strategy targeting MTH1 gene for NSCLC therapy. STATEMENT OF SIGNIFICANCE: CRISPR/Cas9 as a powerful tool for genome editing has drawn much attention. The long-lasting effect possesses unique advantage in cancer treatment. Non-viral vectors have high loading capacity, high safety and low immunogenicity, playing an important role in CRISPR/Cas9 delivery. In our study, a multifunctional non-viral vector for the efficient delivery of CRISPR/Cas9 plasmid was constructed. With the active targeting ligand and nuclei-targeting component, the cargo was efficiently delivered into cell nuclei and exerted genome editing effect. By using this vector, we successfully inhibited the growth and induced the apoptosis of non-small cell lung cancer by disrupting MTH1 expression with good safety. Our work provided an efficient non-vial vector for CRISPR/Cas9 delivery and explored the possibility for cancer treatment.
Insights
A novel non-viral vector effectively delivers CRISPR/Cas9 to cancer cells, disrupting the MTH1 gene to inhibit non-small cell lung cancer growth and metastasis.
Area of Science:
- Biotechnology and Biomedical Engineering
- Cancer Research and Therapeutics
- Gene Editing Technologies
Background:
- The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system offers programmable genome editing with potential for long-lasting cancer treatment effects.
- Efficient and safe delivery of CRISPR/Cas9 is crucial for its clinical application, with a need for advanced non-viral vectors.
- Current non-viral vectors require enhancement for tumor cell targeting and nuclear delivery of CRISPR/Cas9 payloads.
Purpose of the Study:
- To develop a multifunctional non-viral vector for efficient delivery of CRISPR/Cas9 plasmids into cancer cells.
- To enable active targeting of tumor cells and facilitate nuclear delivery of the genome editing machinery.
- To investigate the therapeutic potential of CRISPR/Cas9-mediated MTH1 gene disruption in non-small cell lung cancer (NSCLC).
Main Methods:
- Construction of a multifunctional non-viral vector, PS@HA-Lip, incorporating protamine sulfate (PS) for DNA condensation and nuclear targeting, and liposomes coated with hyaluronic acid (HA) for active tumor cell targeting.
- Encapsulation of CRISPR/Cas9 plasmids within the PS@HA-Lip vector to protect against nuclease degradation.
- In vitro and in vivo evaluation of the vector's ability to deliver CRISPR/Cas9 into NSCLC cells, induce MTH1 gene editing, and assess therapeutic outcomes.
Main Results:
- The PS@HA-Lip vector successfully delivered CRISPR/Cas9 plasmids into the nuclei of tumor cells, inducing genome editing.
- Disruption of the MTH1 gene using CRISPR/Cas9 significantly inhibited non-small cell lung cancer growth.
- Treatment promoted apoptosis in tumor tissues and reduced liver metastasis, demonstrating therapeutic efficacy and safety.
Conclusions:
- A novel multifunctional non-viral vector (PS@HA-Lip) enables efficient CRISPR/Cas9 delivery and genome editing in NSCLC.
- Targeting the MTH1 gene with CRISPR/Cas9 represents a promising therapeutic strategy for non-small cell lung cancer.
- This study provides a viable non-viral delivery system for CRISPR/Cas9, advancing its application in cancer therapy.
More Related Videos
10:42A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
Published on: December 12, 2017
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
Related Concept Videos
CRISPR/Cas9 Genome Editing
CRISPR